The FDA has approved the biologics license application (BLA) for the subcutaneous (SC) administration of pembrolizumab ...
Carotuximab (ENV105) plus standard-of-care hormone therapy apalutamide (Erleada) demonstrated a progression-free survival ...
Following its Type A meeting with the FDA, Replimune reported that a forward pathway “has not been determined” to obtain ...
FDA fast track is intended to expedite the development of therapies that fill serious unmet medical needs. With this ...
ADG126 is a novel anti–CTLA-4 agent incorporating protease-cleavable masking technology that enables tumor-specific ...
Dr Kelly Paulson shares groundbreaking insights from the DeLLphi-303 study, highlighting new immunotherapy strategies for small cell lung cancer treatment.
During a live event, Taha Al-Juhaishi, MD, discussed long-term outcomes of treating blastic plasmacytoid dendritic cell neoplasm and how to navigate toxicities and transplant.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback